211 related articles for article (PubMed ID: 28662433)
1. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
2. CXCR5
Jin Y; Lang C; Tang J; Geng J; Song HK; Sun Z; Wang J
Int Immunopharmacol; 2017 Dec; 53():42-48. PubMed ID: 29032029
[TBL] [Abstract][Full Text] [Related]
3. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
Qiu H; Gong S; Xu L; Cheng H; Gao L; Chen J; Hu X; Yang J
Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma.
Zhou Y; Zha J; Lin Z; Fang Z; Zeng H; Zhao J; Luo Y; Li Z; Xu B
Exp Cell Res; 2018 Jan; 362(2):287-292. PubMed ID: 29174982
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and function of CD4
Cha Z; Gu H; Zang Y; Wang Z; Li J; Huang W; Qin A; Zhu L; Tu X; Cheng N; Song H; Qian B
Int Immunopharmacol; 2018 Aug; 61():132-139. PubMed ID: 29870918
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 10 enhanced CD8+ T cell activity and reduced CD8
Qiu H; Hu X; Gao L; Chen L; Chen J; Yuan J; Huang C; Xu X; Yang J
Exp Cell Res; 2017 Nov; 360(2):146-152. PubMed ID: 28870600
[TBL] [Abstract][Full Text] [Related]
7. Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway.
Cha Z; Qian G; Zang Y; Gu H; Huang Y; Zhu L; Li J; Liu Y; Tu X; Song H; Qian B
Exp Cell Res; 2017 Jan; 350(1):154-160. PubMed ID: 27888017
[TBL] [Abstract][Full Text] [Related]
8. CXCR5
Xing J; Zhang C; Yang X; Wang S; Wang Z; Li X; Yu E
Exp Cell Res; 2017 Jul; 356(1):57-63. PubMed ID: 28412245
[TBL] [Abstract][Full Text] [Related]
9. CXCR5
Jiang H; Li L; Han J; Sun Z; Rong Y; Jin Y
DNA Cell Biol; 2017 Apr; 36(4):321-327. PubMed ID: 28157399
[TBL] [Abstract][Full Text] [Related]
10. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
11. CXCR5
Zhou Y; Guo L; Sun H; Xu J; Ba T
Int Immunopharmacol; 2018 Sep; 62():114-119. PubMed ID: 30005226
[TBL] [Abstract][Full Text] [Related]
12. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
13. CD8
E J; Yan F; Kang Z; Zhu L; Xing J; Yu E
Hum Immunol; 2018 Jun; 79(6):446-452. PubMed ID: 29544815
[TBL] [Abstract][Full Text] [Related]
14. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
15. Circulating CD4
Ding R; Gao W; He Z; Wu F; Chu Y; Wu J; Ma L; Liang C
Int Immunopharmacol; 2017 Nov; 52():318-323. PubMed ID: 28985621
[TBL] [Abstract][Full Text] [Related]
16. Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer.
Ma QY; Chen J; Zhao J
Immunol Res; 2020 Feb; 68(1):54-62. PubMed ID: 32128664
[TBL] [Abstract][Full Text] [Related]
17. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
18. Inverse relationship between CD40L expression and cytolytic molecule expression by CD8
Xing J; Li X; E J; Wang C; Wang H
Exp Cell Res; 2020 Apr; 389(1):111892. PubMed ID: 32035135
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
20. CXCR5
Bai M; Zheng Y; Liu H; Su B; Zhan Y; He H
Exp Cell Res; 2017 Dec; 361(1):39-45. PubMed ID: 28965867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
